HUE062393T2 - Glatiramer-acetátot tartalmazó depórendszerek - Google Patents

Glatiramer-acetátot tartalmazó depórendszerek

Info

Publication number
HUE062393T2
HUE062393T2 HUE17845658A HUE17845658A HUE062393T2 HU E062393 T2 HUE062393 T2 HU E062393T2 HU E17845658 A HUE17845658 A HU E17845658A HU E17845658 A HUE17845658 A HU E17845658A HU E062393 T2 HUE062393 T2 HU E062393T2
Authority
HU
Hungary
Prior art keywords
glatiramer acetate
depot systems
depot
systems
glatiramer
Prior art date
Application number
HUE17845658A
Other languages
English (en)
Inventor
Ehud Marom
Kimelman Nadav Bleich
Uri Danon
Shai Rubnov
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of HUE062393T2 publication Critical patent/HUE062393T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Epoxy Resins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Chemical Vapour Deposition (AREA)
HUE17845658A 2016-08-31 2017-08-09 Glatiramer-acetátot tartalmazó depórendszerek HUE062393T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662381598P 2016-08-31 2016-08-31

Publications (1)

Publication Number Publication Date
HUE062393T2 true HUE062393T2 (hu) 2023-11-28

Family

ID=61300274

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17845658A HUE062393T2 (hu) 2016-08-31 2017-08-09 Glatiramer-acetátot tartalmazó depórendszerek

Country Status (20)

Country Link
US (1) US20210283209A1 (hu)
EP (2) EP4252849A3 (hu)
JP (1) JP7193448B2 (hu)
CN (1) CN109982712A (hu)
AU (1) AU2017319728A1 (hu)
BR (1) BR112019003594A2 (hu)
CA (1) CA3035147A1 (hu)
DK (1) DK3506921T3 (hu)
ES (1) ES2952044T3 (hu)
FI (1) FI3506921T3 (hu)
HR (1) HRP20230738T1 (hu)
HU (1) HUE062393T2 (hu)
IL (2) IL301455B2 (hu)
LT (1) LT3506921T (hu)
MX (1) MX2019002284A (hu)
PL (1) PL3506921T3 (hu)
PT (1) PT3506921T (hu)
RS (1) RS64445B1 (hu)
SI (1) SI3506921T1 (hu)
WO (1) WO2018042415A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3503907B1 (en) 2016-08-28 2024-03-13 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition
US11931357B2 (en) 2022-03-17 2024-03-19 Mapi Pharma Ltd. Depot systems comprising Cariprazine or salts thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PL2949335T3 (pl) 2009-08-20 2017-07-31 Yeda Research & Development Company, Ltd. Terapia octanem glatirameru podawanym z niewielką częstotliwością
CA2784394C (en) * 2010-01-04 2016-12-13 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
CA2808907A1 (en) * 2010-08-20 2012-02-23 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
EP3478300B1 (en) * 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3503907B1 (en) * 2016-08-28 2024-03-13 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate

Also Published As

Publication number Publication date
IL264914B2 (en) 2023-08-01
IL301455B2 (en) 2024-04-01
WO2018042415A1 (en) 2018-03-08
EP3506921A1 (en) 2019-07-10
IL301455B1 (en) 2023-12-01
FI3506921T3 (fi) 2023-07-21
IL301455A (en) 2023-05-01
DK3506921T3 (da) 2023-07-31
JP2019530648A (ja) 2019-10-24
RS64445B1 (sr) 2023-09-29
PT3506921T (pt) 2023-08-07
IL264914B1 (en) 2023-04-01
EP4252849A2 (en) 2023-10-04
ES2952044T3 (es) 2023-10-26
US20210283209A1 (en) 2021-09-16
SI3506921T1 (sl) 2023-10-30
EP4252849A3 (en) 2023-11-01
JP7193448B2 (ja) 2022-12-20
EP3506921A4 (en) 2020-05-06
PL3506921T3 (pl) 2023-08-21
MX2019002284A (es) 2019-09-04
EP3506921B1 (en) 2023-05-17
BR112019003594A2 (pt) 2019-05-21
LT3506921T (lt) 2023-08-10
AU2017319728A1 (en) 2019-02-07
CN109982712A (zh) 2019-07-05
IL264914A (hu) 2019-04-30
HRP20230738T1 (hr) 2023-10-27
CA3035147A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
HK1252464A1 (zh) 氣霧劑輸送系統
GB201802840D0 (en) Aerosol delivery systems
SG11202100791UA (en) Cross-blockchain interaction systems
PL3621466T3 (pl) System dostarczania pary
GB201715895D0 (en) Time-delimited action suggestion system
GB201714300D0 (en) Vapour provision systems
GB201720849D0 (en) Vapour provision systems
PL3672433T3 (pl) Układy dostarczania pary
ZA202002261B (en) Vapour provision systems
IL247302B (en) Systems for releasing materials based on polymer emulsions
IL301455B2 (en) Storage systems containing glatiramer acetate
GB201806508D0 (en) Systems
GB2539952B (en) Location systems
IL275124A (en) Improved flight systems
GB201713679D0 (en) Vapour provision systems
IL275515A (en) Steam supply systems
PL3164492T3 (pl) Układy ekspresji polipeptydu
GB201505067D0 (en) Rendering systems
GB201717231D0 (en) Sheerlock ramp systems limited
GB201718462D0 (en) Vapour provision systems
GB201719205D0 (en) Gaming systems
GB201713680D0 (en) Vapour provision systems
IL256783A (en) Polyhipe-based substance-releasing systems
GB201712561D0 (en) Delivery system
GB201622339D0 (en) Multicook Systems